From the Guidelines
Taking Januvia (sitagliptin) with gastroparesis is not recommended due to the potential worsening of gastroparesis symptoms, and alternative diabetes medications should be considered. Januvia is a DPP-4 inhibitor that works by increasing incretin hormones, which can slow gastric emptying and potentially worsen gastroparesis symptoms like nausea, vomiting, and abdominal discomfort 1. Although DPP-4 inhibitors like Januvia generally have less impact on gastric emptying than GLP-1 receptor agonists, individual responses vary, and caution is advised when using these medications in patients with gastroparesis 2, 3.
Some key points to consider when evaluating the use of Januvia in patients with gastroparesis include:
- The potential for worsening gastroparesis symptoms, such as nausea, vomiting, and abdominal discomfort
- The need for alternative diabetes medications that do not significantly affect stomach emptying
- The importance of regular monitoring of both blood sugar levels and gastroparesis symptoms if Januvia is prescribed
- The need for healthcare providers to evaluate the specific situation of each patient, considering the severity of their gastroparesis, diabetes control needs, and other medications they are taking
It is essential to note that the most recent and highest-quality study, published in 2025, does not provide specific guidance on the use of Januvia in patients with gastroparesis, but it does highlight the importance of considering the potential effects of diabetes medications on gastrointestinal motility 1. Therefore, healthcare providers should exercise caution when prescribing Januvia to patients with gastroparesis and consider alternative treatment options.
From the Research
Gastroparesis and Januvia
- Gastroparesis is a condition characterized by delayed gastric emptying, and its symptoms include nausea, vomiting, abdominal fullness, and early satiety 4, 5, 6, 7.
- The management of gastroparesis involves assessment and correction of nutritional state, relief of symptoms, improvement of gastric emptying, and in diabetics, glycemic control 6.
- There is no direct evidence in the provided studies regarding the use of Januvia with gastroparesis.
- However, it is known that Januvia (sitagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes, and some DPP-4 inhibitors may affect gastrointestinal motility 7.
Pharmacologic Treatments for Gastroparesis
- The only FDA-approved medication for gastroparesis is metoclopramide, which acts as a dopamine receptor antagonist to improve gastric emptying and has an anti-emetic effect 8.
- Other medications used to treat gastroparesis include prokinetic and antiemetic agents, pharmacologic agents targeting the pylorus, and effects of neuromodulators 7.
- There is still a considerable unmet need for efficacious medications specifically for the treatment of gastroparesis, especially in refractory cases 7.
Considerations for Patients with Gastroparesis
- Patients with gastroparesis should be managed by a multidisciplinary team, including gastroenterologists, dietitians, and other healthcare professionals 6.
- Treatment strategies for gastroparesis should be individualized based on the patient's symptoms, nutritional status, and response to therapy 6.
- Further research is needed to develop new and effective therapies for the treatment of gastroparesis 7.